Levetiracetam Wockhardt (Levetiracetam)

Levetiracetam works by binding to the synaptic vesicle protein SV2A, which modulates neurotransmitter release. This action stabilises neuronal firing and reduces excessive excitatory activity, helping to prevent the spread of seizure activity in the brain.

The specific dose of Levetiracetam Wockhardt is determined by the prescribing clinician based on the patient’s age, weight, renal function, and seizure type. Healthcare professionals individualise the regimen to achieve optimal seizure control while minimising adverse effects.

Safety data for levetiracetam during pregnancy and lactation are limited. It is classified as pregnancy category unknown, so it should only be used when the potential benefit justifies the potential risk to the fetus. Breastfeeding mothers should consult their healthcare provider before use.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Levetiracetam offers a favourable safety profile and minimal drug‑enzyme interactions compared with many older anticonvulsants such as carbamazepine or phenytoin. Unlike valproate, it does not affect hepatic metabolism, making it a useful option for patients on multiple medications, though individual response varies.

Levetiracetam Wockhardt should be stored at 2‑8 °C (refrigerated), protected from light, and must not be frozen or shaken. Keep the product in its original packaging until use to maintain stability and potency.

Levetiracetam Wockhardt is supplied as an intravenous injection. It must be administered by a qualified healthcare professional, typically as a slow infusion over several minutes, following the dosing instructions provided by the prescriber.

Serious risks include severe allergic reactions (rash, swelling, breathing difficulty), significant mood or behavioral changes such as depression or suicidal thoughts, and rare blood disorders like thrombocytopenia or neutropenia. Patients should be monitored closely for these events.

Levetiracetam is contraindicated in individuals with known hypersensitivity to levetiracetam or any of its excipients. Patients with severe renal impairment should not use it without dose adjustment, and those with a history of serious psychiatric disorders should be evaluated carefully before initiation.